Acute responses to inhalation of Iloprost in patients with pulmonary hypertension

Chinese Medical Journal

Volumn 125, Issue 16, 2012, Pages 2826-2831

  Zhang, Hong liang ^a   Liu, Zhi hong ^a   Wang, Yong ^a   Xiong, Chang ming ^a   Ni, Xin hai ^a   He, Jian GUO ^a   Luo, Qin ^a   Zhao, Zhi hui ^a   Zhao, Qing ^a   Sun Dr , Xing guo ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Hemodynamics; Iloprost; Pulmonary arterial hypertension; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; DIAZEPAM; ILOPROST;

ADOLESCENT; ADULT; ARTICLE; BLOOD GAS ANALYSIS; BLOOD OXYGEN TENSION; BLOOD PRESSURE; CLINICAL TRIAL; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; FEMALE; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMIC PARAMETERS; HUMAN; INHALATION; LUNG ARTERY PRESSURE; LUNG RESISTANCE; MAJOR CLINICAL STUDY; MALE; PULMONARY HYPERTENSION; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; CHINA; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST;

EID: 84865395804     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.16.005     Document Type: Article

References (31)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
2. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest 2004; 126: 35S-62S.
3. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
4. Schrader BJ, Inbar S, Kaufmann L, Vestal RE, Rich S. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension. J Am Coll Cardiol 1992; 19: 1060-1064.
5. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1354-1360.
6. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
7. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
8. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hyperten sion in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
9. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
10. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
11. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
12. Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203.
13. Petkov V, Ziesche R, Mosgoeller W, Schenk P, Vonbank K, Stiebellehner L, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56: 734-736.
14. Yurtseven N, Karaca P, Uysal G, Ozkul V, Cimen S, Tuygun AK, et al. A comparison of the acute hemodynamic effects of inhaled nitroglycerin and iloprost in patients with pulmonary hypertension undergoing mitral valve surgery. Ann Thorac Cardiovasc Surg 2006; 12: 319-323.
15. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-1304.
16. Schermuly RT, Schulz A, Ghofrani HA, Breitenbach CS, Weissmann N, Hildebrand M, et al. Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. J Aerosol Med 2006; 19: 353-363.
17. Mohan P, Brutsaert DL, Sys SU. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins. Cardiovasc Res 1995; 29: 637-640.
18. Rebsamen MC, Church DJ, Morabito D, Vallotton MB, Lang U. Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocytes. Am J Physiol 1997; 273: E922-E931.
19. Rex S, Missant C, Claus P, Buhre W, Wouters PF. Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit Care 2008; 12: R113.
20. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 2007; 175: 846-850.
21. Rimoldi O, Pierini S, Pagani MR, Pagani M. Reduced cardiovascular sympathetic excitatory responses during iloprost infusion in conscious dogs. Cardiovasc Res 1991; 25: 793-801.
22. Lanier SM, Malik KU. Inhibition by prostaglandins of adrenergic transmission in the left ventricular myocardium of anesthetized dogs. J Cardiovasc Pharmacol 1985; 7: 653-659.
23. Fontana M, Olschewski H, Olschewski A, Schluter KD. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol 2007; 151: 779-786.
24. Rimeika D, Sanchez-Crespo A, Nyren S, Lindahl SG, Wiklund CU. Iloprost inhalation redistributes pulmonary perfusion and decreases arterial oxygenation in healthy volunteers. Acta Anaesthesiol Scand 2009; 53: 1158-1166.
25. Krug S, Hammerschmidt S, Pankau H, Wirtz H, Seyfarth HJ. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008; 76: 154-159.
26. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820-824.
27. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
28. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995; 75: 55A-62A.
29. Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation 2006; 113: 2509-2515.
30. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Hervé P. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: 195S-199S.
31. Klings ES, Hill NS, Ieong MH, Simms RW, Korn JH, Farber HW. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999; 42: 2638-2645.